TABLE 1.
Demographics—liver histology and comorbidities—and variation with PNPLA3 genotype
| Variables | PNPLA3 genotyping |
P-values— overall |
||
|---|---|---|---|---|
| CC | CG | GG | ||
| Patients (n, % of all patients) | 88 (61.1%) | 44 (30.6%) | 12 (8.3%) | |
| BMI (kg/m2) | 45.8 ± 7.4 | 47.0 ± 6.6 | 50.7 ± 12.0 | 0.13 |
| Age (years) | 48.3 ± 11.0 | 46.8 ± 10.2 | 49.0 ± 10.4 | 0.69 |
| Liver histology (n, %) | ||||
| Simple steatosis or normal | 52 (59%) | 16 (36%) | 4 (33%) | 0.01 |
| NASH | 36 (41%) | 28 (64%) | 8 (67%) | 0.01 |
| NASH with FS 0–1 | 29 (33%) | 23 (52%) | 5 (42%) | 0.10 |
| NASH with FS 2–4 | 7 (8%)⊤ | 5 (11%) | 3 (25%)⊤ | 0.17 |
| Type 2 DMA total patients (n, %) | 28 (32%) | 21 (48%) | 7 (58%) | 0.07 |
| IDDM (n, %) | 5 (6%) | 6 (14%) | 4 (33%) | 0.009 |
| OSAS (n, %) | 61 (69%) | 31 (71%) | 8 (67%) | 0.96 |
| Metabolic syndrome (n, %) | 62 (71%) | 32 (76%) | 9 (75%) | 0.83 |
| HOMA-IR > 2.6 (n, %)* | 63 (73%) | 37 (88%) | 8 (80%) | 0.15 |
| Hypertension (n, %) | 47 (54%) | 31 (71%) | 9 (75%) | 0.09 |
| Anticholesterol medication | 23 (26%) | 17 (39%) | 6 (50%) | 0.13 |
P-values derived using a Pearson χ2 test of the 2 × 3 table (e.g., IDDM vs. rs738409C>G genotype).
FS, fibrosis stage; OSAS, obstructive sleep apnea.